Beckman Coulter Life Sciences hits 270 IVDR compliant reagents

In what it says is an industry first, laboratory automation and innovation specialists Beckman Coulter Life Sciences is offering more than 270 reagents for flow cytometry that are IVDR compliant and that are available immediately. This is three years in advance of the deadline set by the European Union.

To keep up with demand, the company has grown its network of certified manufacturing sites to include Marseille, France; County Clare, Ireland; Suzhou, China; Bangalore, India; and Miami, Florida in the United States. 

The In Vitro Diagnostic Regulation (IVDR) is designed to ensure that IVD products achieve the highest levels of safety and efficiency. It replaces the In Vitro Diagnostics Directive (98/79/EC) (IVDD), which has been followed since 1993. This change heavily impacts labs using Laboratory-Developed Tests (LDTs) or “in-house IVDs,” which constitute most clinical flow cytometry tests. The next important deadline with regards to IVDR and LDTs is May 2024. 

Dr. Andreas Böehmler, director of clinical solutions product management for the Global Flow Cytometry Business Unit, said: “Workflow changes to support IVDR can take several months if not more than a year to fully and successfully implement, so now is the critical time to clear through the confusion and make necessary changes to be IVDR compliant. We know this is a marathon and not a sprint, which is why we started this process in 2018 and continue to lead the way to help guide customers to take the required steps to avoid a potential and costly laboratory shutdown. While this impacts countries including the European Union, we know the world is watching, with IVDR to potentially become a global standard.” 

Beckman Coulter Life Sciences has also achieved listing status on the official European Database on Medical Devices (EUDAMED). Customers can view the entire IVDR portfolio by searching for our listed manufacturing site in Marseille, Immunotech SAS. 

Industry leaders agree that with just more than a year until the deadline for LDTs or “in-house IVDs,” the time to begin examining laboratory needs to ensure IVDR compliance is here. 

Dr. Pieter Bogaert, device compliance senior expert at Qarad, a company specialising in regulatory affairs and quality systems for the IVD and medical device industry, said: “Now is the time to start preparing the future of your non-CE marked assays that you're currently running in the laboratory. The instructions for use of reagents will have a much more crucial role under the IVDR than they did under the IVDD.”

IVDR-compliant single-colour antibodies from Beckman Coulter Life Sciences are platform-independent and intended to be used in conjunction with other antibodies for multicolour panel design. Conjugated IVDR-compliant antibodies can be used for diagnosis, monitoring, or prognosis of patients with haematological abnormalities, neoplasms, disorders, immunodeficiencies, or autoimmune disease.